View Older Stories View More Recent Stories
-
Increasing unusual option volume: TERN CORN IVZ ATLX SPCE
-
Merck launches tender offer to acquire Terns Pharmaceuticals for $53 per share
-
William Blair Shuffles Analyst Conviction List for April 2026
-
Truist Securities Downgrades Terns Pharmaceuticals (TERN) to Hold
-
Barclays Downgrades Terns Pharmaceuticals (TERN) to Equalweight
-
Mizuho Downgrades Terns Pharmaceuticals (TERN) to Neutral on Merck acquisition
-
Increasing unusual call option volume: TERN ORBS REAL VGZ DOC BZAI TXG TWO AIRS FSK
-
Increasing unusual option volume: TERN RXT REAL ORBS HDB PD BWA VGZ
-
Citizens Downgrades Terns Pharmaceuticals (TERN) to Market Perform
-
TD Cowen Downgrades Terns Pharmaceuticals (TERN) to Hold
-
Terns Pharmaceuticals Inc. (TERN)
-
Mizuho on Terns Pharmaceuticals (TERN): MRK acquisition 'makes sense on multiple levels'
-
H.C. Wainwright Downgrades Terns Pharmaceuticals (TERN) to Neutral
-
Truist Securities stays Buy on Terns Pharmaceuticals (TERN) as Merck acquires 'for a steal'
-
Merck to buy oncology firm Terns Pharmaceuticals in $6.7 billion deal
-
Terns Pharmaceuticals Inc. (TERN) call put ratio 1 call to 1.2 puts into Merck (MRK) to acquire
-
Merck (MRK) Nears $6b Deal To Buy Terns Pharma (TERN) - FT
-
Increasing unusual call option volume: PSA TERN IRM ADMA HIMX MRK BCE BNO GROY
-
Increasing unusual option volume: TERN XLB BKLN GROY HIMX BIZD ADMA
-
Leerink Partners Starts Terns Pharmaceuticals (TERN) at Outperform
-
Terns Pharmaceuticals Inc. (TERN) call put ratio 86 calls to 1 put with a focus on April calls as share price up 9.7%
-
William Blair on Terns Pharmaceuticals (TERN): 'stock Remains Our 2026 Top Pick
-
(TERN) PT Raised to $57 at Citizens After TERN-701 Shown to be Best-in-Class
-
Terns Pharmaceuticals (TERN) PT Raised to $70 at Jefferies
-
Terns Pharmaceuticals (TERN) PT Raised to $54 at Mizuho
-
Terns Pharmaceuticals (TERN) PT Raised to $60 at H.C. Wainwright
-
Terns Pharmaceuticals Inc. (TERN) files mixed shelf
-
BMO Capital Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals (TERN) PT Raised to $58 at Oppenheimer
-
Terns Pharmaceuticals Inc. (TERN) Halted, News Pending
-
Terns Pharmaceuticals Inc. (TERN) halted, news pending
-
These stocks are new additions to Mizuho's 'Americas Top Picks' list
-
Mizuho Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals (TERN) PT Raised to $35 at Citizens: Becoming Best-in-Class
-
Terns Pharmaceuticals (TERN) PT Raised to $35 at Truist Securities
-
Terns Pharmaceuticals (TERN) PT Raised at BMO Capital on 'Strong ASH Data'
-
H.C. Wainwright Upgrades Terns Pharmaceuticals (TERN) to Buy
-
Terns Pharmaceuticals (TERN) PT Raised to $28 at Truist Securities
-
Terns Pharmaceuticals (TERN) PT Raised to $24 at Oppenheimer
-
William Blair Upgrades Terns Pharmaceuticals (TERN) to Outperform
-
Terns presents positive TERN-701 data at ASH meeting
-
H.C. Wainwright Reiterates Neutral Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals (TERN) PT Lowered to $15 at Citizens After TERN-601 Development Stopped
-
Terns Pharmaceuticals (TERN) PT Lowered to $17 at Oppenheimer
-
After-hours movers: Netflix, Intuitive Surgical, DraftKings, Texas Instruments
-
Truist Securities Starts Terns Pharmaceuticals (TERN) at Buy
-
Citizens Reiterates Market Outperform Rating on Terns Pharmaceuticals (TERN)
-
Barclays Starts Terns Pharmaceuticals (TERN) at Overweight
-
Mizuho Reiterates Outperform Rating on Terns Pharmaceuticals (TERN)
-
Terns Pharmaceuticals Inc. (TERN) Presents Positive Data from Phase 1 Study of TERN-601

